Clinical Trial

Clinical Study of EZH2 Inhibitor Combined With PARP Inhibitor in the Treatment of Patients With Advanced or Recurrent Epithelial Ovarian Cancer.

Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This study evaluates the efficacy and safety of Zeprumetostat in combination with Fuzuloparib for the treatment of patients with advanced or recurrent ovarian epithelial carcinoma, with the primary endpoint being Objective Response Rate (ORR).
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-01-05.
Trial Details
NCT Number NCT07339553
Lead Sponsor Peking University Third Hospital
Conditions Ovariancancer, Platinum-sensitive Recurrent
Enrollment 30 participants
Start Date 2026-01-04
Primary Completion 2029-01-30 (estimated)
Study Completion 2029-02-26 (estimated)
Updated on ClinicalTrials.gov 2026-01-21